×
About 388 results

ALLMedicine™ Acquired Thrombotic Thrombocytopenic Purpura Center

Research & Reviews  123 results

Benchmarking the centralized urgent plasma exchange service for patients admitted with ...
https://doi.org/10.1002/jca.21916
Journal of Clinical Apheresis; Seheult JN, Stram MN et. al.

Jun 26th, 2021 - Consensus guidelines recommend that therapeutic plasma exchange (TPE) should be started within 4 to 8 hours after the diagnosis of suspected acquired thrombotic thrombocytopenic purpura (aTTP). This study aimed to audit the steps from diagnosis to...

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 v...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237075
Journal of Thrombosis and Haemostasis : JTH; Maayan H, Kirgner I et. al.

Jun 10th, 2021 - In December 2020 the Israeli Health Ministry began a mass vaccination campaign with the BNT162b2 vaccine. This was an important step in overcoming the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic. Autoimmune phenomenon ha...

Fatal cerebral hemorrhage in a patient with thrombotic thrombocytopenic purpura with a ...
https://doi.org/10.1080/09537104.2021.1922883
Platelets Ditzel K, Mons DJ et. al.

May 13th, 2021 - Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy with a severe mortality and morbidity. Caplacizumab has recently been approved in the Netherlands as a new therapeutic option in patients with life-threatening org...

Clinical characteristics and outcomes of adult patients with acquired thrombotic thromb...
https://doi.org/10.21037/apm-21-759
Annals of Palliative Medicine; Huang F, Li XP et. al.

May 13th, 2021 - Thrombotic thrombocytopenic purpura (TTP) is a rare disease and a potentially life-threatening thrombotic microangiopathy. Although the diagnostic and therapeutic techniques have improved, it is still difficult for clinicians to identify early due...

Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothr...
https://doi.org/10.1007/s11239-021-02406-6 10.1111/j.1538-7836.2006.01753.x 10.1056/NEJMra1705454 10.1515/cclm-2017-0502 10.1515/cclm-2016-0676 10.1177/0961203315579091 10.1155/2018/3287491 10.1016/j.thromres.2017.07.001 10.1097/mbc.0000000000000512 10.1182/blood-2004-11-4490 10.1182/blood-2003-05-1616 10.1111/j.1365-2141.2008.07074.x
Journal of Thrombosis and Thrombolysis; Yun J, Gu J et. al.

Apr 30th, 2021 - Although a few antiphospholipid syndrome (APS) occurs with acquired thrombotic thrombocytopenic purpura (TTP), the relationship between antiphospholipid antibodies (aPL) and anti-ADAMTS13 (anti-a disintegrin and metalloprotease with thrombospondin...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  2 results

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
https://clinicaltrials.gov/ct2/show/NCT02553317

May 22nd, 2019 - The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)
https://clinicaltrials.gov/ct2/show/NCT01151423

Aug 11th, 2015 - The purpose of this study is to determine whether anti-von Willebrand factor Nanobody is safe and effective as adjunctive treatment in patients with acquired thrombotic thrombocytopenic purpura (TTP). Patients will receive either placebo or anti-v...

see more →

News  27 results

NICE Recommends Innovative Treatment for Severe Blood Disorder for NHS Use
https://www.medscape.com/viewarticle/941022

Nov 16th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

A new era of TTP treatment
https://www.mdedge.com/hematology-oncology/article/196522/bleeding-disorders/new-era-ttp-treatment?channel=41022
Kristin S. Ricci, MD

Mar 18th, 2019 - Earlier this year, the Food and Drug Administration approved Cablivi (caplacizumab-yhdp) (Sanofi Genzyme, Cambridge, Mass. ) for the treatment of acquired thrombotic thrombocytopenic purpura (TTP), making it the first medication specifically indica.

Edible Weed Triggers MI; A Heart-Shaped Question; Pivotal Year for PCSK9s
https://www.medpagetoday.com/cardiology/prevention/78063

Feb 18th, 2019 - A marijuana lollipop apparently triggered a heart attack in a 70-year-old man with stable coronary artery disease hoping for pain relief and better sleep. (Canadian Journal of Cardiology) The FDA approved caplacizumab-yhdp (Cablivi) as the first t...

FDA approves caplacizumab for aTTP
https://www.mdedge.com/clinicianreviews/article/194030/bleeding-disorders/fda-approves-caplacizumab-attp?channel=27979
Jennifer Smith

Feb 6th, 2019 - The Food and Drug Administration has approved caplacizumab (Cablivi) in combination with plasma exchange and immunosuppressive therapy for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP). Caplacizumab is an anti–vo.

Acquired TTP Drug Wins Approval
https://www.medpagetoday.com/hematologyoncology/hematology/77859

Feb 6th, 2019 - WASHINGTON -- Caplacizumab (Cablivi), an antibody drug targeting von Willebrand factor, is now approved for acquired thrombotic thrombocytopenic purpura (aTTP), the FDA said Wednesday. The drug is to be given in combination with plasma exchange an...

see more →